Alnylam Pharmaceuticals (ALNY) Given a $156.00 Price Target at Jefferies Group
Jefferies Group set a $156.00 price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities analysts also recently weighed in on the stock. Nomura upped their price target on shares of Alnylam Pharmaceuticals to $86.00 and gave the stock a sell rating in a research note on Friday. BMO Capital Markets dropped their price target on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an outperform rating on the stock in a research note on Friday. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $128.00 to $118.00 and set an equal weight rating on the stock in a research note on Friday. Leerink Swann upped their price target on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a market perform rating in a research note on Thursday, January 25th. Finally, B. Riley reaffirmed a buy rating and issued a $205.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $126.98.
Shares of Alnylam Pharmaceuticals (ALNY) opened at $117.30 on Friday. The stock has a market capitalization of $11,530.00, a price-to-earnings ratio of -21.68 and a beta of 2.68. Alnylam Pharmaceuticals has a 1-year low of $44.50 and a 1-year high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 30,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $5,639,435. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Maraganore sold 74,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the transaction, the chief executive officer now directly owns 223,710 shares in the company, valued at $28,379,850.60. The disclosure for this sale can be found here. Insiders have sold 220,409 shares of company stock worth $28,667,017 over the last three months. Company insiders own 4.30% of the company’s stock.
Several large investors have recently modified their holdings of the company. Eaton Vance Management grew its position in shares of Alnylam Pharmaceuticals by 15.7% in the fourth quarter. Eaton Vance Management now owns 36,866 shares of the biopharmaceutical company’s stock valued at $4,684,000 after purchasing an additional 5,000 shares during the last quarter. Alexandria Capital LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $18,602,000. Suntrust Banks Inc. grew its position in shares of Alnylam Pharmaceuticals by 8.1% in the fourth quarter. Suntrust Banks Inc. now owns 9,944 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 746 shares during the last quarter. American International Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $255,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $353,000. 88.59% of the stock is currently owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.